Asset Details
Do you wish to reserve the book?
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
Do you wish to request the book?
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
2020
Overview
Mutation-derived neoantigens are taking central stage as a determinant in eliciting effective antitumor immune responses following adoptive T-cell therapies. These mutations are patient-specific, and their targeting calls for highly personalized pipelines. The promising clinical outcomes of tumor-infiltrating lymphocyte (TIL) therapy have spurred interest in generating T-cell infusion products that have been selectively enriched in neoantigen (or autologous tumor) reactivity. The implementation of an isolation step, prior to T-cell
expansion and reinfusion, may provide a way to improve the overall response rates achieved to date by adoptive T-cell therapies in metastatic cancer patients. Here we provide an overview of the main technologies [i.e., peptide major histocompatibility complex (pMHC) multimers, cytokine capture, and activation markers] to enrich infiltrating or circulating T-cells in predefined neoantigen specificities (or tumor reactivity). The unique technical and regulatory challenges faced by such highly specialized and patient-specific manufacturing T-cell platforms are also discussed.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Animals
/ Antigens
/ Antigens, Neoplasm - immunology
/ Cells
/ Epitopes, T-Lymphocyte - immunology
/ Humans
/ Immunotherapy, Adoptive - methods
/ Lymphocyte Activation - immunology
/ Lymphocytes, Tumor-Infiltrating - immunology
/ Lymphocytes, Tumor-Infiltrating - metabolism
/ Major histocompatibility complex
/ Melanoma
/ Mutation
/ Patients
/ Peptides
/ Precision Medicine - methods
/ Reagents
/ T-Cell Antigen Receptor Specificity
/ T-Lymphocyte Subsets - immunology
